RecruitingPhase 3

Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)

Sweden5,160 participantsStarted 2021-12-02

Plain-language summary

Prediabetes is associated to an increased risk of cardiovascular disease and mortality. Although metformin can delay progression to diabetes there is a lack of RCTs evaluating the effect of metformin on cardiovascular outcomes. MIMET aims to investigate if addition of metformin to standard care has effects on the occurrence of cardiovascular events after acute myocardial infarction in patients with newly detected prediabetes (identified by oral glucose tolerance test, HbA1c or fasting glucose levels).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. HbA1c 42-47 mmol/mol or
✓. Capillary or venous fasting plasma glucose concentration 6.1-6.9 mmol/L or
✓. 2-hour post-load capillary glucose concentration 8.9-12.1 mmol/L or
✓. 2-h post-load venous plasma glucose concentration 7.8-11.0 mmol/L
✓. HbA1c \<48 mmol/mol and 2-hour post-load capillary glucose concentration \>12.1 mmol/L or 2-h post-load venous plasma glucose concentration \>11.0 mmol/L (thus elevated 2-hour glucose levels in the diabetes range but without HbA1c levels diagnostic for diabetes)

What they're measuring

Time to major CV event

Timeframe: Estimated follow-up for each patient is 1-4 years

Trial details

NCT IDNCT05182970

SponsorKarolinska Institutet

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05

Contact for this trial

Anna Norhammar, MD, Prof.

+46858701568 anna.norhammar@ki.se

View on ClinicalTrials.gov More PreDiabetes trials